Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study

作者：Fernando C. Barros, Robert B. Gunier, Albertina Rego, Loı̈c Sentilhes, Stephen Rauch, Serena Gandino, Jagjit S. Teji, Jim Thornton, Alisa Kachikis, Ricardo Nieto, Rachel Craik, Paolo Ivo Cavoretto, Adele Winsey, Paola Roggero, Gabriel B Rodriguez, Valeria Savasi, Erkan Kalafat, Francesca Giuliani, Marta Fabre, Anne Caroline Benski, Irma A. Coronado-Zarco, Stefania Livio, Adela Ostrovska, Nerea Maíz, Fabiola R. Castedo Camacho, Ashley Peterson, Philippe Deruelle, Carolina Giudice, Roberto Casale, Laurent Salomon, Constanza P. Soto Conti, Federico Prefumo, Ehab Zakaria Mohamed Elbayoumy, Marynéa Silva do Vale, Valéria Hernández, Katherine Chandler, Milagros Risso, Emily Marler, Daniela M. Cáceres, Guadalupe Albornoz Crespo, Ernawati Ernawati, Michal Lipschuetz, Shabina Ariff, Ken Takahashi, Carmen Vecchiarelli, Teresa Hubka, Satoru Ikenoue, Gabriela Tavchioska, Babagana Bako, Adejumoke Idowu Ayede, Brenda Eskenazi, Zulfiqar A Bhutta, Stephen Kennedy, Aris T. Papageorghiou, José Villar · 发表于：American Journal of Obstetrics and Gynecology · 年份：2024 · DOI：10.1016/j.ajog.2024.02.008 · 被引用次数：35 · 研究领域：COVID-19 Impact on Reproduction、Vaccine Coverage and Hesitancy、SARS-CoV-2 and COVID-19 Research

BACKGROUND: In early 2023, when Omicron was the variant of concern, we showed that vaccinating pregnant women decreased the risk for severe COVID-19-related complications and maternal morbidity and mortality. OBJECTIVE: This study aimed to analyze the impact of COVID-19 during pregnancy on newborns and the effects of maternal COVID-19 vaccination on neonatal outcomes when Omicron was the variant of concern. STUDY DESIGN: INTERCOVID-2022 was a large, prospective, observational study, conducted in 40 hospitals across 18 countries, from November 27, 2021 (the day after the World Health Organization declared Omicron the variant of concern) to June 30, 2022, to assess the effect of COVID-19 in pregnancy on maternal and neonatal outcomes and to assess vaccine effectiveness. Women diagnosed with laboratory-confirmed COVID-19 during pregnancy were compared with 2 nondiagnosed, unmatched women recruited concomitantly and consecutively during pregnancy or at delivery. Mother-newborn dyads were followed until hospital discharge. The primary outcomes were a neonatal positive test for COVID-19, severe neonatal morbidity index, severe perinatal morbidity and mortality index, preterm birth, neonatal death, referral to neonatal intensive care unit, and diseases during the neonatal period. Vaccine effectiveness was estimated with adjustment for maternal risk profile. RESULTS: We enrolled 4707 neonates born to 1577 (33.5%) mothers diagnosed with COVID-19 and 3130 (66.5%) nondiagnosed mothers. ...